NextCure, Inc. (NXTC)
NASDAQ: NXTC · Real-Time Price · USD
1.690
+0.045 (2.74%)
Jun 29, 2026, 1:57 PM EDT - Market open
NextCure Employees
NextCure had 40 employees as of December 31, 2025. The number of employees decreased by 3 or -6.98% compared to the previous year.
Employees
40
Change (1Y)
-3
Growth (1Y)
-6.98%
Revenue / Employee
n/a
Profits / Employee
-$1,366,600
Market Cap
6.10M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| BioAtla | 41 |
| Aptevo Therapeutics | 33 |
| Cardio Diagnostics Holdings | 17 |
| Soligenix | 14 |
| XTL Biopharmaceuticals | 10 |
| Purple Biotech | 10 |
| CNS Pharmaceuticals | 8 |
| Can-Fite BioPharma | 5 |
NXTC News
- 11 days ago - NextCure Transcript: AGM 2026 - Transcripts
- 25 days ago - NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers - GlobeNewsWire
- 27 days ago - NextCure Transcript: KOL event - Transcripts
- 27 days ago - NextCure Press release: KOL event - Filings
- 27 days ago - NextCure Slides: KOL event - Filings
- 27 days ago - NextCure share weakness overdone, says Lucid Capital - TheFly
- 4 weeks ago - NextCure presents Phase 1 data for SIM0505 in gynecologic cancers - TheFly
- 4 weeks ago - NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026 - GlobeNewsWire